JP3732090B2 - 全アナライトの測定方法 - Google Patents
全アナライトの測定方法 Download PDFInfo
- Publication number
- JP3732090B2 JP3732090B2 JP2000531741A JP2000531741A JP3732090B2 JP 3732090 B2 JP3732090 B2 JP 3732090B2 JP 2000531741 A JP2000531741 A JP 2000531741A JP 2000531741 A JP2000531741 A JP 2000531741A JP 3732090 B2 JP3732090 B2 JP 3732090B2
- Authority
- JP
- Japan
- Prior art keywords
- analyte
- assay
- surfactant
- plasma
- cyclodextrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 63
- 239000012491 analyte Substances 0.000 claims abstract description 68
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 41
- 239000003352 sequestering agent Substances 0.000 claims abstract description 32
- 230000009870 specific binding Effects 0.000 claims abstract description 28
- 238000009739 binding Methods 0.000 claims abstract description 20
- 108091008324 binding proteins Proteins 0.000 claims abstract description 15
- 238000002156 mixing Methods 0.000 claims abstract description 8
- 238000000159 protein binding assay Methods 0.000 claims abstract description 7
- 239000004094 surface-active agent Substances 0.000 claims description 69
- 229920000858 Cyclodextrin Polymers 0.000 claims description 53
- 102000004889 Interleukin-6 Human genes 0.000 claims description 49
- 108090001005 Interleukin-6 Proteins 0.000 claims description 49
- 229940100601 interleukin-6 Drugs 0.000 claims description 49
- 238000003556 assay Methods 0.000 claims description 47
- XJWSAJYUBXQQDR-UHFFFAOYSA-M dodecyltrimethylammonium bromide Chemical group [Br-].CCCCCCCCCCCC[N+](C)(C)C XJWSAJYUBXQQDR-UHFFFAOYSA-M 0.000 claims description 45
- 238000003018 immunoassay Methods 0.000 claims description 44
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical group O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 42
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 20
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 19
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims description 19
- 102000005962 receptors Human genes 0.000 claims description 19
- 102000023732 binding proteins Human genes 0.000 claims description 14
- 239000000700 radioactive tracer Substances 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 238000000926 separation method Methods 0.000 claims description 9
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 6
- 238000002821 scintillation proximity assay Methods 0.000 claims description 6
- 210000001124 body fluid Anatomy 0.000 claims description 5
- 239000010839 body fluid Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 2
- 239000011541 reaction mixture Substances 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 abstract description 31
- 230000027455 binding Effects 0.000 abstract description 18
- 239000003599 detergent Substances 0.000 abstract description 9
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 239000013060 biological fluid Substances 0.000 abstract 1
- 210000002381 plasma Anatomy 0.000 description 98
- 102000004190 Enzymes Human genes 0.000 description 33
- 108090000790 Enzymes Proteins 0.000 description 33
- 239000012131 assay buffer Substances 0.000 description 29
- 238000005259 measurement Methods 0.000 description 23
- 239000000872 buffer Substances 0.000 description 22
- 238000011084 recovery Methods 0.000 description 20
- 108020003175 receptors Proteins 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 238000002965 ELISA Methods 0.000 description 13
- 239000000427 antigen Substances 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 12
- 230000003287 optical effect Effects 0.000 description 12
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 9
- 108010090804 Streptavidin Proteins 0.000 description 9
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 8
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 8
- 238000010494 dissociation reaction Methods 0.000 description 8
- 230000005593 dissociations Effects 0.000 description 8
- 229940116886 human interleukin-6 Drugs 0.000 description 8
- 230000009871 nonspecific binding Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000011324 bead Substances 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000003127 radioimmunoassay Methods 0.000 description 7
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 6
- 239000004743 Polypropylene Substances 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- -1 polypropylene Polymers 0.000 description 6
- 229920001155 polypropylene Polymers 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 102000003992 Peroxidases Human genes 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 5
- 229960005156 digoxin Drugs 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 108040007629 peroxidase activity proteins Proteins 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 4
- 238000011891 EIA kit Methods 0.000 description 4
- 238000008157 ELISA kit Methods 0.000 description 4
- 239000001116 FEMA 4028 Substances 0.000 description 4
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 4
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 4
- 229960004853 betadex Drugs 0.000 description 4
- 229940097362 cyclodextrins Drugs 0.000 description 4
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 4
- 239000013024 dilution buffer Substances 0.000 description 4
- 238000003094 enzyme-multiplied immunoassay technique Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 102000005936 beta-Galactosidase Human genes 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 3
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 238000002875 fluorescence polarization Methods 0.000 description 3
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 2
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 2
- 108010032595 Antibody Binding Sites Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 2
- 102000013460 Malate Dehydrogenase Human genes 0.000 description 2
- 108010026217 Malate Dehydrogenase Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 239000006249 magnetic particle Substances 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- 229960001860 salicylate Drugs 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229940034208 thyroxine Drugs 0.000 description 2
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000270272 Coluber Species 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 244000195452 Wasabia japonica Species 0.000 description 1
- 235000000760 Wasabia japonica Nutrition 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000052611 human IL6 Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical compound [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000012035 limiting reagent Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98301126.3 | 1998-02-16 | ||
| EP98301126 | 1998-02-16 | ||
| PCT/GB1999/000515 WO1999041609A1 (en) | 1998-02-16 | 1999-02-15 | Method for measurement of total analyte |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002503812A JP2002503812A (ja) | 2002-02-05 |
| JP2002503812A5 JP2002503812A5 (enExample) | 2005-12-22 |
| JP3732090B2 true JP3732090B2 (ja) | 2006-01-05 |
Family
ID=8234671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000531741A Expired - Lifetime JP3732090B2 (ja) | 1998-02-16 | 1999-02-15 | 全アナライトの測定方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6692921B1 (enExample) |
| EP (1) | EP1057021B1 (enExample) |
| JP (1) | JP3732090B2 (enExample) |
| AT (1) | ATE360206T1 (enExample) |
| CA (1) | CA2321090C (enExample) |
| DE (1) | DE69935850T2 (enExample) |
| DK (1) | DK1057021T3 (enExample) |
| ES (1) | ES2285830T3 (enExample) |
| WO (1) | WO1999041609A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102006015001A1 (de) * | 2006-03-31 | 2007-10-11 | NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen | Verfahren zum Nachweis und/oder zur Anreicherung von Analytproteinen und/oder Analytpeptiden aus einer komplexen Proteinmischung |
| GB2437545B (en) * | 2006-04-28 | 2011-07-06 | Novexin Ltd | Dextrin-containing reagents for detecting and quantifying proteins |
| DE102008011578A1 (de) * | 2008-02-28 | 2009-09-03 | Endress + Hauser Conducta Gesellschaft für Mess- und Regeltechnik mbH + Co. KG | Photolumineszenz-Sensor |
| DE102008040513B4 (de) * | 2008-07-17 | 2010-08-26 | BAM Bundesanstalt für Materialforschung und -prüfung | Verwendung einer langwellig emittierenden Cyaninverbindung als NIR-Fluoreszenzstandard und Kit zur Kalibrierung von Photolumineszenzmesssystemen |
| US10048254B2 (en) | 2013-06-04 | 2018-08-14 | Albany Medical College | Cyclic-di-AMP specific detection |
| JP6226624B2 (ja) * | 2013-08-08 | 2017-11-08 | 田中貴金属工業株式会社 | 溶血性レンサ球菌診断イムノクロマト試薬、キット及び検出方法 |
| WO2015089172A1 (en) | 2013-12-13 | 2015-06-18 | Siemens Healthcare Diagnostics Inc. | Pretreatment agent in non-agglutination assays |
| JP7355140B2 (ja) * | 2022-02-28 | 2023-10-03 | 住友ベークライト株式会社 | セリンプロテアーゼの検出用または測定用試薬 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4956274A (en) * | 1987-04-06 | 1990-09-11 | Microgenics Corporation | Reagent stabilization in enzyme-donor and acceptor assay |
| JPH01126400A (ja) * | 1987-07-29 | 1989-05-18 | Microgenics Corp | シクロデキストリン洗浄組成物 |
| US5032503A (en) * | 1988-06-22 | 1991-07-16 | Microgenics Corporation | Liquid single reagent for air enzyme complementation assay |
| GB9100551D0 (en) * | 1991-01-10 | 1991-02-20 | Amersham Int Plc | Method and reagent for eliminating analytical interference in enzymatic analysis from substances used for extraction of intracellular metabolites |
| US5705345A (en) * | 1991-01-10 | 1998-01-06 | Amersham International Plc | Methods and kits for preparing nucleic acids using cyclodextrin |
| JP3055036B2 (ja) * | 1991-04-25 | 2000-06-19 | 株式会社ヤトロン | 生体成分測定方法及び測定用試薬キット |
| US5516647A (en) * | 1993-11-05 | 1996-05-14 | Abbott Laboratories | Compounds useful as alkaline phosphatase inhibitors and therapeutic agents |
| US5646005A (en) * | 1994-04-28 | 1997-07-08 | Kudsk; Kenneth A. | Use of an IL-6 assay for predicting the development of post-trauma complications |
| DE69831522T2 (de) * | 1997-03-03 | 2006-06-14 | Amersham Biosciences Uk Ltd | In-situ Zellextraktion und Assay-Verfahren |
-
1999
- 1999-02-15 ES ES99905094T patent/ES2285830T3/es not_active Expired - Lifetime
- 1999-02-15 EP EP99905094A patent/EP1057021B1/en not_active Expired - Lifetime
- 1999-02-15 DK DK99905094T patent/DK1057021T3/da active
- 1999-02-15 DE DE69935850T patent/DE69935850T2/de not_active Expired - Lifetime
- 1999-02-15 US US09/622,106 patent/US6692921B1/en not_active Expired - Lifetime
- 1999-02-15 CA CA002321090A patent/CA2321090C/en not_active Expired - Fee Related
- 1999-02-15 JP JP2000531741A patent/JP3732090B2/ja not_active Expired - Lifetime
- 1999-02-15 WO PCT/GB1999/000515 patent/WO1999041609A1/en not_active Ceased
- 1999-02-15 AT AT99905094T patent/ATE360206T1/de active
Also Published As
| Publication number | Publication date |
|---|---|
| ATE360206T1 (de) | 2007-05-15 |
| EP1057021B1 (en) | 2007-04-18 |
| DE69935850D1 (de) | 2007-05-31 |
| EP1057021A1 (en) | 2000-12-06 |
| ES2285830T3 (es) | 2007-11-16 |
| WO1999041609A1 (en) | 1999-08-19 |
| CA2321090A1 (en) | 1999-08-19 |
| US6692921B1 (en) | 2004-02-17 |
| DK1057021T3 (da) | 2007-08-06 |
| DE69935850T2 (de) | 2008-01-10 |
| CA2321090C (en) | 2006-04-11 |
| JP2002503812A (ja) | 2002-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5031148B2 (ja) | Ｃ反応性蛋白についての免疫測定 | |
| Akhavan-Tafti et al. | A homogeneous chemiluminescent immunoassay method | |
| US9383354B2 (en) | Anti-antibody reagent | |
| US4504585A (en) | Affinity immunoassay system | |
| JPS6188155A (ja) | フイコビリタンパク質による螢光エネルギ−転位 | |
| JPH0421818B2 (enExample) | ||
| US12416627B2 (en) | Immunoassay with enhanced sensitivity | |
| CN114910635A (zh) | 一种无基质效应的均相免疫检测试剂盒及其应用 | |
| JP3732090B2 (ja) | 全アナライトの測定方法 | |
| Clarke et al. | Immunoassays | |
| CN1217193C (zh) | 心肌肌钙蛋白鲁米诺化学发光免疫分析检测方法 | |
| Zou et al. | Rapid determination of hazardous compounds in food based on a competitive fluorescence microsphere immunoassay | |
| JP3847983B2 (ja) | 免疫学的分析用試薬、免疫学的分析方法及び免疫学的分析用キット | |
| EP0863402B1 (en) | In-situ cell extraction and assay method | |
| Ivanova et al. | Magnetic nanoparticle‐based fluorescent immunoassay for determination of progesterone in milk | |
| JP2007512542A (ja) | 複合体、及び検出方法におけるそれらの使用 | |
| JPH02502122A (ja) | 液体中のリガンドを検出及び定量する方法 | |
| JP3922622B2 (ja) | 新規な蛍光プローブ類、これらを組み合わせたメタンフェタミンの測定キットおよびメタンフェタミンの簡易測定法 | |
| EP0248038A1 (en) | Idiotypic-antigenic conjunction binding assay | |
| Seydack | Immunoassays: basic concepts, physical chemistry and validation | |
| WO1987006006A1 (en) | Anti-enzyme antibody immunoassay | |
| Schwickart et al. | Immunoassays | |
| Nara et al. | A novel enzyme-linked immunosorbent assay for cortisol using a long-chain biotinylated cortisol-3-CMO derivative | |
| Holazová | Bioanalytical Methods | |
| Rubenstein | New Homogeneous Assay Methods for the Determination of Proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041124 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041124 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20050914 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050920 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20051011 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091021 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091021 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101021 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101021 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111021 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121021 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121021 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131021 Year of fee payment: 8 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |